Akebia Therapeutics Inc — Balance Sheet (NASDAQ:AKBA) | MetaTrader

Open full chart

Financials

Overview 声明 Statistics

Quarterly Annual

Total assets 644.14 M525.55 M351.83 M241.7 M220.67 M376.56 M Total liabilities 396.52 M449.09 M342.49 M272.29 M269.86 M343.95 M Total equity 247.62 M76.46 M9.34 M30.58 M49.19 M32.61 M Total liabilities & shareholders' equities 644.14 M525.55 M351.83 M241.7 M220.67 M376.56 M Total debt —————— Net debt ——————

新闻

Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript

Akebia在Leerink会议上发言:战略聚焦Vafseo及产品管线

Akebia at Leerink Conference: Strategic Focus on Vafseo and Pipeline

3 Best Stocks to Buy Today with 125%+ Upside, 2/27/2026, According to Top Analysts - TipRanks.com

Ardelyx (ARDX) Reports Break-Even Earnings for Q4

Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Akebia Therapeutics签署新总部租约并修改高管离职协议

Akebia Therapeutics signs new headquarters lease and amends executive severance agreements

Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts (NASDAQ:AKBA)

Akebia在罕见肾脏疾病试验中给首位患者用药

Akebia reports first patient dosed in rare kidney disease trial

Akebia Therapeutics begins phase 2 trial for rare kidney disease drug